Literature DB >> 1796044

Solution stability of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB.

A Riggin1, D Clodfelter, A Maloney, E Rickard, E Massey.   

Abstract

A 3-month solution stability study at 5 degrees C of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB indicated that phosphate-buffered saline solutions at pH 4.5-5.5 had little tendency to lose vinca by hydrolysis, improved vinca stability, showed acceptable physical stability, and formed minimal amounts of soluble aggregates compared to solutions at pH 6.5-7.4. Hydrolysis and aggregation with concomitant loss of stability were accelerated at 30 degrees C throughout the pH range investigated. As determined by ELISA, the binding properties of KS1/4-DAVLB to tumor antigens were not affected by pH or temperature. A formulation suitable for initial clinical trials in cancer patients is described.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1796044     DOI： 10.1023/a:1015899612117

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


  8 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Drug localisation and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in a human tumour xenograft.

Authors:  G F Rowland; R G Simmonds; V A Gore; C H Marsden; W Smith
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  A reversed-phase high-performance liquid chromatographic method for characterization of biosynthetic human growth hormone.

Authors:  R M Riggin; G K Dorulla; D J Miner
Journal:  Anal Biochem       Date:  1987-11-15       Impact factor: 3.365

Review 4.  KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.

Authors:  T F Bumol; A L Baker; E L Andrews; S V DeHerdt; S L Briggs; M E Spearman; L D Apelgren
Journal:  Targeted Diagn Ther       Date:  1988

5.  Isolation and characterization of the human adenocarcinoma-associated glycoprotein gp40.

Authors:  J R Sportsman; L D Taber; M C Slisz; L D Apelgren; T F Bumol
Journal:  Biotechnol Appl Biochem       Date:  1988-12       Impact factor: 2.431

6.  Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody.

Authors:  T F Bumol; P Marder; S V DeHerdt; M J Borowitz; L D Apelgren
Journal:  Hybridoma       Date:  1988-08

7.  Protein assays for monoclonal antibodies.

Authors:  E C Rickard; G S Sittampalam; D K Clodfelter
Journal:  Biotechniques       Date:  1988 Nov-Dec       Impact factor: 1.993

8.  Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.

Authors:  M E Spearman; R M Goodwin; L D Apelgren; T F Bumol
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030
  8 in total
  1 in total

1.  Is stability prediction possible for protein drugs? Denaturation kinetics of beta-galactosidase in solution.

Authors:  S Yoshioka; Y Aso; K Izutsu; S Kojima
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.